Simple Summary Surgery is the only potential cure for pancreatic ductal adenocarcinoma
and should always be combined with adjuvant chemotherapy or other multimodal treatment …

Pancreatic ductal adenocarcinoma (PDAC) remains a dismal prognosis and surgery is the
only chance for cure. However, only few of the patients have localized tumor eligible for …

Simple Summary Pancreatic cancer remains one of the most dreaded cancers worldwide.
The incidence of this relatively rare cancer is increasing by almost 1.0% per year. It is …

Pancreatic ductal adenocarcinoma is a common malignancy of the gastrointestinal tract. The
number of new cases diagnosed and the number of deaths each year are almost identical …

The surgical treatment of pancreas ductal adenocarcinoma (PDAC) is plagued by high rates
of distant recurrences despite complete resection, highlighting the importance of systemic …

Background Current treatment of potentially resectable pancreatic ductal adenocarcinoma
(PDAC) includes pancreatic resection followed by adjuvant therapy. Aim of this study is to …

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant. While cancers in other
organs have shown clear improvements in 5‐year survival, the 5‐year survival rate of …

Pancreatic ductal adenocarcinoma (PDAC) remains to be a therapeutic challenge as only
15%‐20% of all patients present with resectable tumor stages by the time of diagnosis. In the …

Results For the entire population, the median survival (MS) was 18.4 months; the 1-year
relapse-free survival was 56%, and the 5-year overall survival (OS) was 13%. The size of the …

Background Multimodal treatment concepts enhance options for surgery in locally advanced
pancreatic ductal adenocarcinoma (PDAC). This review provides an overview of technical …